MARKET

PMN

PMN

Promis Neuroscie
NASDAQ
13.30
+0.57
+4.48%
Opening 15:49 02/09 EST
OPEN
13.23
PREV CLOSE
12.73
HIGH
13.97
LOW
12.70
VOLUME
37.12K
TURNOVER
--
52 WEEK HIGH
39.75
52 WEEK LOW
6.27
MARKET CAP
28.63M
P/E (TTM)
-0.7144
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PMN last week (0202-0206)?
Weekly Report · 11h ago
ProMIS Neurosciences Is Maintained at Buy by Guggenheim
Dow Jones · 3d ago
ProMIS Neurosciences Price Target Cut to $35.00/Share From $125.00 by Guggenheim
Dow Jones · 3d ago
Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $35
Benzinga · 3d ago
Guggenheim Remains a Buy on ProMIS Neurosciences (PMN)
TipRanks · 3d ago
ABG Management Ltd. Reports Acquisition of ProMIS Neurosciences Common Shares
Reuters · 3d ago
ProMIS Neurosciences nimmt am Guggenheim Emerging Outlook: Biotech Summit teil
Reuters · 4d ago
ProMIS Neurosciences to Participate in Guggenheim Emerging Outlook Biotech Summit
Reuters · 4d ago
More
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Webull offers Promis Neurosciences Inc stock information, including NASDAQ: PMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMN stock methods without spending real money on the virtual paper trading platform.